SCHEMBL22056124

SCHEMBL22056124

CC(C)(C)OC(=O)Nc1ccc(C(=O)N2CCCC(C(=O)Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 20/20 0.80
▸ CDK9 P50750 14/20 0.80
▸ CDK7 P50613 13/20 0.80
▸ CCNT1 O60563 6/20 0.80
▸ CCNH P51946 6/20 0.80
▸ MNAT1 P51948 6/20 0.80
▸ CCNA1 P78396 6/20 0.80
▸ CCNE1 P24864 7/20 0.66
▸ CDK14 O94921 2/20 0.66
▸ CDK1 P06493 2/20 0.66
▸ CCNB1 P14635 2/20 0.66
▸ CDK8 P49336 2/20 0.66
▸ CDK3 Q00526 2/20 0.66
▸ CDK5 Q00535 2/20 0.66
▸ CDK16 Q00536 2/20 0.66
▸ CDK13 Q14004 2/20 0.66
▸ CDK5R1 Q15078 2/20 0.66
▸ CDK12 Q9NYV4 2/20 0.66
▸ CCNK O75909 1/20 0.66
▸ CCNC P24863 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18613898 0.92 CDK2 (0.84) CDK2CDK9CDK7CCNT1CCNH
SCHEMBL22056129 0.90 CDK2 (0.80) CDK2CDK9CDK7CCNT1CCNH
SCHEMBL20582973 0.89 CDK2 (1.00) CDK2CDK9CDK7CCNT1CCNH
SCHEMBL22056125 0.89 CDK2 (0.79) CDK2CDK9CDK7CCNT1CCNH
Hydrochloric Acid SCHEMBL18613948 0.88 CDK2 (0.78) CDK2CDK9CDK7CCNT1CCNH
SCHEMBL6184407 0.87 CDK2 (0.70) CDK2CDK9CDK7CCNT1CCNH
SCHEMBL20583376 0.87 CDK2 (0.88) CDK2CDK9CDK7CCNT1CCNH
SCHEMBL20583378 0.87 CDK2 (0.88) CDK2CDK9CDK7CCNT1CCNH
SCHEMBL21128620 0.82 CDK2 (0.71) CDK2CDK9CDK7CCNT1CCNH
SCHEMBL22056315 0.82 CDK2 (0.73) CDK2CDK9CDK7CCNT1CCNH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4019515-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES Dana-Farber Cancer Institute, Inc. (US) 2022-06-29 — — EP disclosed
US-20220055998-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-24 — — US disclosed
US-20220055998-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-24 — — US disclosed
US-11142507-B2 Inhibitors of cyclin-dependent kinases DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-10-12 — — US disclosed
US-20200172499-A9 INHIBITORS OF CYCLIN-DEPENDENT KINASES DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-06-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11142507-B2 Inhibitors of cyclin-dependent kinases CDK1, CDK13, CDK3 CDK2 5/4885CDK9 22/4885CDK7 9/4885
US-20200172499-A9 INHIBITORS OF CYCLIN-DEPENDENT KINASES CDK1, CDK13, CDK3 CDK2 5/4885CDK9 22/4885CDK7 9/4885
US-20220055998-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES CDK1, CDK13, CDK3 CDK2 5/4885CDK9 22/4885CDK7 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback